Jazz Pharmaceuticals (JAZZ) Set to Announce Quarterly Earnings on Wednesday

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) is scheduled to be posting its quarterly earnings results after the market closes on Wednesday, November 6th. Analysts expect Jazz Pharmaceuticals to post earnings of $4.56 per share for the quarter. Individual that are interested in registering for the company's earnings conference call can do so using this link.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.80 by $0.87. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1 billion. Jazz Pharmaceuticals had a net margin of 10.10% and a return on equity of 28.65%. On average, analysts expect Jazz Pharmaceuticals to post $16 EPS for the current fiscal year and $19 EPS for the next fiscal year.

Jazz Pharmaceuticals Stock Up 0.5 %

Shares of Jazz Pharmaceuticals stock traded up $0.53 during trading on Wednesday, reaching $112.44. The company had a trading volume of 54,948 shares, compared to its average volume of 669,611. The company has a market cap of $7.09 billion, a price-to-earnings ratio of 23.07, a price-to-earnings-growth ratio of 1.41 and a beta of 0.57. The firm's fifty day moving average is $110.86 and its 200-day moving average is $109.54. The company has a debt-to-equity ratio of 1.36, a quick ratio of 2.02 and a current ratio of 2.37. Jazz Pharmaceuticals has a fifty-two week low of $99.06 and a fifty-two week high of $134.48.

Analyst Upgrades and Downgrades

JAZZ has been the topic of a number of recent analyst reports. Morgan Stanley cut their target price on shares of Jazz Pharmaceuticals from $160.00 to $150.00 and set an "equal weight" rating on the stock in a research note on Friday, July 12th. StockNews.com raised shares of Jazz Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday, August 1st. UBS Group lowered their price objective on shares of Jazz Pharmaceuticals from $117.00 to $113.00 and set a "neutral" rating for the company in a research report on Tuesday, July 2nd. Royal Bank of Canada boosted their price objective on shares of Jazz Pharmaceuticals from $175.00 to $179.00 and gave the company an "outperform" rating in a research report on Wednesday, October 23rd. Finally, HC Wainwright reaffirmed a "buy" rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, August 1st. Three equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $173.43.

Insiders Place Their Bets

In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of the stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $108.30, for a total value of $152,703.00. Following the completion of the transaction, the senior vice president now directly owns 14,531 shares in the company, valued at $1,573,707.30. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 4.20% of the stock is owned by insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.